(54) Title: PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES

(57) Abstract: An improved procedure for the purification of warfarin acid. Sodium, potassium and lithium warfarin salts and the corresponding clathrates are prepared in high, pharmacopeial grade purity and good yields from the pure warfarin acid and the respective metal salt bases in suitable media. The process for preparing pure warfarin acid from crude warfarin acid starts by suspending the crude acid in a water immiscible solvent, extracting the acid into an aqueous solution of dilute base, separating the resulting aqueous phase and diluting it with a lower alkyl alcohol. The aqueous solution is filtered before being diluted with the lower alkyl alcohol. The solution is acidified to a pH of about 2 to 5 using a suitable acid, such as hydrochloric, sulfuric or phosphoric acid. The resulting suspension is stirred at a temperature of from about 20°C to about 60°C, cooling the suspension below room temperature, filtering the pure warfarin acid and drying.
PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a synthesis of pure warfarin acid and derivatives thereof. In particular, the invention relates to a commercially feasible, large scale process for purification of warfarin acid and the preparation of warfarin sodium, warfarin sodium 2-propanol clathrate, warfarin potassium and warfarin lithium 2-propanol clathrate therefrom, in high, pharmacopoeial grades of purity.

Background

Warfarin sodium, warfarin sodium 2-propanol clathrate, warfarin potassium and warfarin lithium 2-propanol clathrate are highly potent anticoagulants, generally administered orally and used extensively as active pharmaceutical ingredients (APIs). These compounds are also widely used as rodenticides in different dosages and formulations.

The commercial production of APIs preferably uses systems and processes capable of providing high quality, pure intermediates and products complying with pharmacopoeial requirements. Numerous procedures for the synthesis of warfarin acid, its salts and clathrates exist, but there is still a need by the pharmaceutical industry for methods of preparing these compounds in high quality as both intermediates and products and particularly for the preparation of high purity warfarin acid.

Warfarin acid and its alkali metal salts are coumarinic type derivatives having powerful anticoagulant properties. They are useful, established vitamin K related anticoagulant pharmaceuticals for the treatment of humans and animals. For example:

- Warfarin sodium and its 2-propanol clathrate is marketed under various commercial names like Coumadin; Marevan; Prothromadin; Tintorane; Warfarin sodium; Warfilone; Waran.
- Warfarin potassium salt is available under the name Athrombin K.

These substances are also the active component in common rodenticide agents.

Warfarin acid, known chemically as racemic 4-hydroxy-3-(3-oxo-phenylbutyl)-2H-1-benzopyran-2-one or 3-(α-acetonylbenzyl)-4-hydroxycoumarin, is typically prepared by the Michael addition reaction of commercially available or in situ prepared 4-hydroxycoumarin to 4-phenyl-3-buten-2-one (benzalacetone). A wide range of conditions, for example,
variations in solvents, variation of acidic and basic catalysts, varying temperatures, etc., have been used in synthetic procedures described in the literature. Although warfarin acid is a well known chemical entity, a simple, commercially feasible and direct preparation of warfarin acid in the pure state has not been significantly addressed.

Earlier purification methods described by Ikawa et al. (U.S. Patent No. 2,427,578, see also, J. Am. Chem Soc. 1944, 66, 902) or by Siedman et al. (J. Am. Chem. Soc. 1950, 72, 5193), as well as many others, recrystallize the crude acid from acetone-water mixtures.

U.S. Patent No. 4,113,744 to Badran et al., describes a method for preparation of pure, microcrystalline warfarin acid by dissolution of the commercial impure acid into a special amine buffered-water system, filtration and reproccipitation of the pure, microcrystalline acid by pH readjustment of the filtrate.

Bush and Trage described a procedure for the preparation of pure warfarin acid, comprising ether extraction of the crude acid, back-extraction with dilute sodium hydroxide, filtration of the alkaline solution, and reproccipitation with 5N HCl solution. (J. of Pharm. Sci. 1983, 72 (7), 830-831.) The pure acid is obtained by further recrystallization from acetone-water.

More recent references (for example, Ivanov et al., Arch. Pharm (Weinheim) 1990, 323, 521-522; Uwaydah et al. WO 97/24347) describe extraction/recrystallization procedures using glacial acetic acid or ethyl acetate.

Warfarin alkali salts, chemically known as 4-hydroxy-3-(3-oxo-phenylbutyl)2H-1-benzopyran-2-one alkali salts or 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium, potassium or lithium salts, are usually prepared by reacting warfarin acid with a molar equivalent or less of the respective alkali metal bases in aqueous medium, or with the metal alkoxides in lower alkyl alcohols.

U.S. Patent No. 2,765,321 to Schroeder et al. describes a process of preparing crystalline warfarin sodium by reacting an aqueous sodium hydroxide solution with an excess of warfarin acid, followed by removal of the acid excess by addition of ethanol and filtration. The final warfarin sodium salt is obtained through a salting out procedure using lithium chloride addition into the ethanol-water solution of the warfarin sodium salt, cooling and recovering the precipitated warfarin sodium by filtration.

U.S. Patent No. 2,777,859 to Link et al. describes a process of preparing an aqueous solution of warfarin alkali metal derivatives by adding an aqueous alkali metal hydroxide to
an excess of water wet warfarin acid, warming and removing the excess of warfarin acid by filtration.

U.S. Patent No. 3,077,481 to Schroeder et al. describes a process of purifying colored warfarin sodium by dissolving the amorphous salt in warm 2-propanol, cooling the resulting solution and recovering the crystalline warfarin sodium 2-propanol clathrate product.

In French Patent 1,397,213, Yates and Thomson describe an improved preparation of warfarin sodium by reacting a suspension of warfarin acid in an anhydrous lower alkyl alcohol with a solution containing a molar equivalent of sodium hydroxide dissolved in the same solvent. The crude product is isolated as a syrup upon solvent evaporation and must be further purified and subjected to thorough drying or lyophilization. The product is normally not of pharmaceutical quality. The warfarin sodium may be purified by dissolving in 2-propanol from which the crystalline clathrate is isolated by filtration. The 2-propanol trapped may be removed by evaporation to dryness in vacuo of the crystalline salt solutions in methanol, ethanol or acetone. Further purification is required in order to obtain a pharmaceutical grade substance.

U.S. Pat. No. 3,192,232 to Schroeder and Link describes a process for preparing warfarin sodium and warfarin potassium salts by reacting a slurry or warfarin acid in acetone-water with less than an equivalent of sodium hydroxide or potassium hydroxide in water at room temperature. The solution of the crude salt is purified by stirring with active charcoal and isolating of the salt by evaporation to dryness, spray drying, or drum drying.

U.S. Pat. No. 3,246,013 to Weiner et al. describes a process for preparing crystalline warfarin sodium 2-propanol clathrate through neutralization of a warfarin acid/2-propanol slurry to a pH of about 9-10 using sodium hydroxide or, as an alternative to avoid the color usually present, using selected sodium alkoxides at about 50-80°C.

Ohnishi et al. have described a method for preparing warfarin alkali metal salts by dissolving warfarin acid in an aqueous solution containing an equivalent amount of the respective alkali metal hydroxide (lithium, sodium, potassium, rubidium and cesium). *Biosci. Biotech. Biochem.* 1995, 59(6), 995-1006 (cf. CA 123: 105246 (1996)) The respective salts are isolated by lyophilization.

In a recent patent publication, WO 97/24347 (published July 10, 1997), Uwaydah et al. describe a comprehensive process for warfarin alkali salts (sodium and potassium) and clathrate preparation starting from 2-hydroxyacetophenone and a carbonate ester. The hydroxycoumarin thus obtained is further reacted with benzalacetone in the presence of a
phase transfer catalyst to give warfarin acid in a procedure similar to those of Ivanov (see reference above). The latter intermediate is further reacted with sodium or potassium hydroxide or carbonate, or preferably with sodium or potassium methoxide or ethoxide in anhydrous ethanol or 2-propanol to ultimately yield the desired product.

As can be seen from the description of existing preparations, there is a great deal of interest in this field, and a number of synthetic routes for the preparation of warfarin acid and its salts exist. However, the need remains for an economical, industrially feasible procedure to produce a high quality, pharmacopeial grade of warfarin acid and related salts.

**SUMMARY OF THE INVENTION**

Further objectives and advantages will become apparent from a consideration of the description, and nonlimiting examples described therein.

The present invention is a process for preparing pure warfarin acid from crude warfarin acid by suspending the crude acid in a water immiscible solvent, preferably toluene, extracting the acid into an aqueous solution of dilute base, separating the resulting aqueous phase and diluting it with a lower alkyl alcohol, for example, methanol, ethanol or, preferably, 2-propanol. Preferably, the aqueous solution is filtered before being diluted with the lower alkyl alcohol. The lower alkyl alcohol is preferably added to a concentration of about 50%. The solution is acidified to a pH of about 2 to 5 using a suitable acid, such as hydrochloric, sulfuric or phosphoric acid and the like. Sulfuric acid is preferred. The resulting suspension is stirred at a temperature of from about 20°C to about 60°C, preferably about 40°C to about 50°C, cooling the suspension below room temperature, preferably to about 5°C to about 10°C, filtering the pure warfarin acid and drying.

The crude warfarin acid for use in the purification is preferably prepared by hydrolyzing cyclocoumarol using about 2% to about 10% of an acidic catalyst which is preferably 4-toluene sulfonic acid, to a solution of cyclocoumarol in a mixture of a polar water miscible solvent and water at a temperature of from about room temperature to about the boiling point of the solvent. Less than 2% acid catalyst is usually inefficient while more than 10-15% may impurify the product and be uneconomical. The reaction is preferably conducted in butanone or acetone containing about 35% to about 65% of water, preferably about 40% to about 50% water, and is most preferably conducting at reflux temperatures.

In another aspect, the invention is a process for the preparation of warfarin sodium 2-propanol clathrate comprising reacting pure warfarin acid with sodium carbonate in 2-propanol. The 2-propanol preferably contains between about 0.5% and about 5% of water by
volume, and more preferably from about 1% to about 3% of water by volume. The molar ratio of sodium carbonate to warfarin acid is preferably between about 0.9 and about 2, and more preferably between about 1.0 and about 1.3, to ensure yield and quality of the final product. The preparation of warfarin sodium 2-propanol clathrate is preferably conducted at a temperature of from about room temperature to about the boiling point of the solvent. More preferably, the reaction is carried out at reflux temperatures. The reaction is typically complete in a time of from about 1 to about 5 hours, and more preferably is completed in from about 2 hours to about 3 hours. In a preferred embodiment, the solids remaining after the reaction is complete, which consist primarily of unreacted sodium carbonate, are removed by filtration. Water is removed by azeotropic distillation by either a binary or ternary system. The preferred binary azeotropic system is 2-propanol and water. Preferred ternary azeotropic distillation systems are 2-propanol-cyclohexane-water, 2-propanol-hexane-water or 2-propanol-heptane-water, preferably 2-propanol-hexane-water. The pure warfarin 2-propanol clathrate precipitates from the reaction mixture as a crystalline pure solid, which is collected by filtration.

In another aspect, the invention is a method for preparing warfarin potassium by reacting pure warfarin acid with potassium carbonate in place of sodium carbonate. The reaction parameters for potassium salt formation are similar to those for warfarin sodium 2-propanol clathrate formation.

In another aspect the invention is a process for preparing warfarin lithium 2-propanol clathrate comprising reacting pure warfarin acid with a solution of lithium 2-propoxide in anhydrous 2-propanol. Preferred parameters are otherwise identical to those for the preparation of warfarin sodium 2-propanol clathrate, although the 2-propanol must be anhydrous.

In yet another aspect, the invention is a process for preparing warfarin sodium comprising reacting pure warfarin acid with sodium carbonate in a water miscible polar solvent other than 2-propanol. Preferably, the water miscible polar solvent is acetone, ethanol, acetonitrile or butanone, and is most preferably butanone. The pure warfarin sodium is collected by solvent removal or addition of a low polarity solvent, for example, hexane, heptane or cycloheptane.

The present invention succeeds where previous efforts have failed by providing a convenient synthesis of pure warfarin acid. The invention is particularly advantageous in
providing for the preparation of warfarin derivatives from the pure warfarin acid allowing use of the derivatives without additional purification.

This invention solves a previously unrecognized problem and provides a method for the preparation of pure warfarin acid enabling the production of higher quality salts and clathrates without the need for additional purification.

This invention presents an improved synthesis of warfarin acid and its derivatives in a crowded and mature art by providing a method for preparing warfarin acid in a pure form not readily obtainable by use of existing methods without additional purification.

This invention provides advantages that were not previously appreciated such as the more efficient synthesis of high purity warfarin alkali metal salts and clathrates.

The invention provides an advantage in producing warfarin acid in the form of large crystals that are more easily filtered, facilitate ease of drying and shorten drying times.

This invention satisfies a long felt need for a convenient, industrially useful synthesis of pure warfarin acid and sodium, potassium and lithium salts and clathrates prepared therefrom.

**DETAILED DESCRIPTION OF THE INVENTION**

In describing preferred embodiments of the present invention, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. All references cited herein are incorporated by reference as if each had been individually incorporated by reference.

"Pure," as used herein, refers to a substance that meets at least one of the standards of the U.S. Pharmacopoeia (USP), British Pharmacopoeia, European Pharmacopoeia (Ph.Eur). EPCRS refers to the European Pharmacopoeial Commission of Reference Substances and USPRS refers to U.S. Pharmacopoeial Reference Standards. The EPCRS and USPRS provide reference standards for warfarin sodium and warfarin acid.

Non-limiting examples of suitable nonpolar solvents include aliphatic and aromatic hydrocarbons, for example, hexane, heptane, cyclohexane, toluene and benzene. Toluene is particularly preferred.

Non-limiting examples of water miscible solvents include lower molecular weight alcohols (methanol, ethanol, isopropanol, etc.), acetonitrile, ketones (acetone, methylethyl ketone, etc.), and ethers (tetrahydorfurane, 1,4-dioxane, etc.).

Extensive research has demonstrated that the purity of warfarin acid used to prepare derivatives has a critical effect on the quality of the final warfarin salts and their usefulness
as APIs. Therefore, a fully reproducible, industrially feasible procedure for the preparation of pure warfarin acid as a key intermediate is presented.

The procedure for preparing pure warfarin acid according to the invention comprises the following:

1) Preparation of a cyclocoumarol derivative by the Michael addition reaction of 4-hydroxycoumarin to benzalacetone in methanol at reflux, using known procedures.

2) Preparation of the crude warfarin acid by acid catalyzed hydrolysis of the cyclocoumarol in a butanone-water or acetone-water system. A preferred acid catalyst is 4-toluene sulfonic acid. The acid concentration is preferably about 2% to about 10% and more preferably about 3% to about 6%. Less than 2% acid is generally inefficient, and greater than 10%-15% leads to increased impurities and may be uneconomical. The butanone or acetone contains about 30% to about 60%, preferably about 40% to about 50%, water. The reaction may be conducted at a temperature from about room temperature to the reflux temperature of the solvent. Preferably, the reaction is conducted at about reflux temperature.

Although other methods of preparing crude warfarin acid may in principle be used, the inventors have found that the purification steps which follow are most effective when crude warfarin acid is prepared by this method.

3) Novel, improved preparation of pure warfarin acid by suspension of the crude acid in a low polarity, water immiscible solvent, dissolution and extraction of the warfarin acid into an aqueous alkaline phase as the warfarin salt, separation, and optionally filtration, of the aqueous alkaline solution followed by dilution with a lower alkyl alcohol, preferably above room temperature. The low polarity water immiscible solvent is preferably non-chlorinated and is most preferably toluene. The alkaline solution is preferably an aqueous solution of a dilute base, for example, sodium hydroxide. A preferred lower alkyl alcohol solvent is 2-propanol, although other lower alkyl alcohols, for example, methanol or ethanol, may be used. The pure, crystalline warfarin acid is preferably isolated by filtration of the precipitated substance. The acid used to precipitate the warfarin acid may be an aqueous acid selected from hydrochloric acid, sulfuric acid, phosphoric acid and the like. Sulfuric acid is preferred.

It has surprisingly been found that the conditions for dilution of the aqueous salt solution and precipitation of the purified warfarin acid are instrumental in obtaining high purity warfarin acid without the need for additional purification procedures which tend to be costly and time consuming. After separating and filtering the aqueous solution of warfarin
acid salt, dilution of the aqueous solution with a lower alkyl alcohol, preferably at or above room temperature, is critical. Accordingly, prior to the addition of the acid, the solution is stirred, preferably at a temperature of from about 20°C to about 60°C, more preferably from about 40°C to about 50°C. The lower alkyl alcohol, preferably 2-propanol, is added at a temperature at or above room temperature. Although the amount of alcohol is not critical, the resultant solution preferably contains from about 30% to about 60% isopropanol, more preferably between about 40% and about 50% isopropanol, to prevent loss of the pure acid. The acid is then added to a pH of about 2-5 at or above room temperature. Precipitation at or above temperature is critical and results in the generation of warfarin acid with higher purity and larger crystals.

After addition of the acid, the suspension is stirred at or above room temperature. Precipitation is further facilitated by cooling the suspension to a temperature below room temperature, preferably from about 5°C to about 10°C. The pure, crystalline warfarin acid is then isolated by filtration of the precipitated substance.

This invention also relates to procedures for preparing pure warfarin derivatives including salts and clathrates. Warfarin derivatives particularly include warfarin sodium, warfarin sodium 2-propanol clathrate, warfarin potassium and warfarin lithium 2-propanol clathrate, from the pure warfarin acid previously described. It will be appreciated that warfarin salts of other ions may be formed and clathrates incorporating solvents other than 2-propanol may be prepared according to the invention.

These procedures comprise the following:

1) Warfarin sodium is prepared by refluxing the pure warfarin acid with an excess of sodium carbonate in a polar solvent such as acetone or butanone, which may be either anhydrous or contain from about 1% to about 10% water. The unreacted sodium carbonate is preferably removed by filtration. The product is isolated by evaporating the solvent to dryness or by precipitating the salt by addition of a nonpolar solvent such as hexane, cyclohexane, heptane and the like, and filtering and drying the precipitate.

2) Warfarin sodium 2-propanol clathrate is prepared by refluxing the pure warfarin acid with an equivalent amount or an excess of sodium carbonate in 2-propanol. The 2-propanol may be anhydrous or may contain about 0.5% to about 10% water, preferably about 1% to about 3% water. The molar ratio of sodium carbonate to warfarin acid is between about 0.9 and about 2, and is preferably between about 1.0 and about 1.3. The reaction may be conducted at a temperature ranging from room temperature to the
boiling point of the solvent for a time of from about 1 hour to about 5 hours. Preferably, the reaction is conducted at reflux temperature and the preferred reaction time is from about 2 hours to about 3 hours. The unreacted carbonate is removed by filtration while the excess water is removed by binary (2-propanol/water) or ternary (heptane, cyclohexane or, preferably, hexane with 2-propanol and water) azeotropic distillation. The precipitated pure warfarin sodium 2-propanol clathrate is further isolated as a pure crystalline solid by filtration and drying.

3) Warfarin potassium salt is prepared by refluxing the pure warfarin acid with potassium carbonate in 2-propanol. Reaction conditions are similar to those for warfarin sodium 2-propanol clathrate. However, when preparing the potassium salt, a clathrate is not formed. The salt is precipitated directly from the reaction medium upon cooling, and is isolated by filtration and drying.

4) Warfarin lithium-2-propanol clathrate is prepared by reacting pure warfarin acid with a small excess of lithium-2-propoxide in 2-propanol (prepared in situ from lithium strips or rods). The product is isolated by cooling, precipitation, filtration and drying.

For the described processes, there are possible variations of some of the conditions which may provide somewhat different results. Some of the varying conditions that might be more preferable are varying time and temperatures, level of stirring, and reaction vessel characteristics. These may be further explored for any particular available equipment and for the respective final product desired. Varying processes to optimize conditions for a particular laboratory setting may be determined by routine experimentation. Such processes would be apparent to persons skilled in the art in light of the teachings of the present invention.

Warfarin derivatives prepared according to the present invention may be made into pharmaceutical dosage forms with appropriate pharmaceutically acceptable carriers or diluents. If appropriate, pharmaceutical dosage forms may be formulated into preparations including, but not limited to, solid, semi-solid, liquid, or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, and aerosols, in the usual ways for their respective route of administration. Methods known in the art can be utilized to prevent release or absorption of the warfarin derivative until it reaches the target organ or to ensure time-release of the composition. A pharmaceutically-acceptable form should be employed which does not ineffectuate the compositions of the present invention. In pharmaceutical dosage forms, the compositions may be used alone or
in appropriate association, as well as in combination with, other pharmaceutically-active compounds.

To illustrate the invention and its particular usefulness, the following non-limiting examples are presented which exemplify the invention, but do not define its full scope:

5 EXAMPLES

EXAMPLE 1: Preparation of Pure Warfarin Acid

The full, two step reaction and purification procedure, starting from cyclocoumarol methyl ether is hereinafter described:

A. Crude warfarin acid by cyclocoumarol hydrolysis

Cyclocoumarol methyl ether (1720 g, previously prepared in 72% yield by the known procedure, using 1.2 kg of benzalacetone, in methanol) was added to a solution of butanone (6.5 L) containing 4-toluene sulfonic acid monohydrate (170 g). Water (4 L) was added and the mixture stirred at reflux for about 4 hours.

The reaction solution was then concentrated to about half of its initial volume by azeotropic distillation of butanone/water, wherein the crude warfarin acid began to precipitate. The suspension was gradually cooled and the crude, wet warfarin acid was obtained by filtration and washed with cold butanone and water.

Yield: 1320-1390 g (80-85% from cyclocoumarol) on a dry basis. (The wet substance contained about 15-25% moisture and was directly used into the next step.)

Physical properties of the crude warfarin acid were identical to an authentic sample (warfarin acid USP standard).

B. Pure warfarin acid from crude warfarin acid

The crude (wet) acid from example 1 was added to toluene (5.5 L) and the mixture stirred at room temperature until a homogeneous suspension was achieved. A solution of 5% sodium hydroxide (about 4 L) was then added to the stirred suspension until a basic pH was reached and an almost clear two-phase solution was obtained. The stirring was stopped and the layers allowed to separate. The lower aqueous phase was filtered by suction and the upper organic phase discarded.

The aqueous filtrate was returned to the vessel and gently warmed to 40–50°C. 2-Propanol (4 L) was added and the solution stirred for about ½ hour while maintaining the temperature.
Sulfuric acid (20% solution in water) was then added slowly in portions to the warm, stirred solution, until a constant acidic pH was achieved. A total of about 1.5-2 L of sulfuric acid solution was needed, while the pure warfarin acid precipitated as a bright-white crystalline solid.

The thick suspension was stirred for an additional ½ hour, then cooled to below 10°C for another hour.

The cold suspension was filtered, thoroughly washed with demineralized water and finally with cold 2-propanol.

The pure warfarin was obtained as a white crystalline powder upon drying in a vacuum oven for 8-10 hours.

Yield: 1250-1300 g (90-95% from the crude acid)
M.P.: 159.6-161.2°C (lit. 161°C)
Clarity and color: clear and almost colorless.
Color by UV absorption at 385 nm (of the 10% w/v solution in 1N NaOH): < 0.30 AU.

Related substances (TLC): none detected.
Physical properties of the product were identical to warfarin acid USP/RS.

EXAMPLE 2: Preparation of Warfarin Sodium

A three-neck, round bottom flask provided with mechanical stirrer, thermometer and reflux/distillation condenser was successively charged with pure warfarin acid, (308 g, 1 mole), sodium carbonate (Merck, art. 106398) (106 g, 1 mole) and butanone (MEK, CP, 3100 ml).

The mixture was heated to reflux with stirring for 8 hours, then cooled to room temperature and filtered.

The clear solution was returned to the flask and the solvent volume reduced to about 1/3 of the initial volume by distillation.

Heptane (3100 ml) was slowly added in portions to the residue in the flask and the mixture stirred at room temperature for an additional 4 hours.

Warfarin sodium was isolated as a white powder by suction filtration, washing and drying to constant weight in a vacuum oven at 35-40°C and 1 mm Hg.

Yield: 298 g (90%)
Clarity of the alkaline solution: clear and colorless (complies with Ph.Eur and USP).
Color (phenolic ketones) by UV absorption: < 0.1 AU (complies with Ph.Eur and USP).

pH of 1% aqueous solution: 7.86 (complies with Ph.Eur and USP).

Related substances (by TLC): not more than 0.1% (complies with Ph.Eur).

Identification (IR): identical with the warfarin sodium EPCR standard.

**EXAMPLE 3: Preparation of Warfarin Sodium**

As per Example 2 above but using pure warfarin acid (0.1 mole) and hexane (300 ml) instead of heptane.

**Yield:** 29 g (88%)

**Clarity:** color (by UV) and related substances as in example 2 above.

**pH:** 7.8

**Analysis:** Identical to EPCR standard.

**EXAMPLE 4: Preparation of Warfarin Potassium**

A mixture of pure warfarin acid (31 g, 0.1 mole) and potassium carbonate (99%) (10.4 g, 0.75 mole) in 2-propanol (CP grade, 160 ml) was stirred at 20-25°C for 2 hours, in a suitable glass flask under a nitrogen atmosphere.

The unclear solution was filtered using suction and the filtrate was cooled to below 5°C for 4-6 hours.

The precipitated solid was carefully filtered by nitrogen pressure, washed with cold 2-propanol and dried in a vacuum oven (40-50°C, 10 mm Hg) for 6-8 hours to give pure warfarin potassium as a white, hygroscopic, crystalline solid.

**Yield:** 24.3 g (70%)

**Identification** (by IR vs. warfarin acid standard): complies

**Potassium test:** positive

**1H-NMR test:** pattern practically identical to warfarin sodium-EPCRS.

**Thermal analysis** (by DSC): no solvent release endotherm observed (in contrast to warfarin sodium 2-propanol clathrate).

Both 1H-NMR and DSC data strongly suggested that warfarin potassium does not form clathrates with 2-propanol.

**EXAMPLE 5: Preparation of Warfarin Lithium 2-Propanol Clathrate**

A solution of lithium 2-propoxide in 2-propanol was prepared by reacting lithium rods, (0.42 g, 0.06 at.-g) with excess 2-propanol (CP anhydrous, 10 ml). This solution was
added dropwise to a stirred suspension of pure warfarin acid (15.4 g, 0.05 mole) in 2-propanol (60 ml), under a nitrogen atmosphere.

The clear solution was stirred at room temperature for two hours until a solid partially precipitated.

The suspension was further cooled to about 0°C for 4 hours, the white solid precipitate was carefully filtered under nitrogen pressure, washed with cold 2-propanol and dried in a vacuum oven (40-50°C, 10 mm Hg) for 8-12 hours to give the pure warfarin lithium 2-propanol clathrate as a white, crystalline powder.

Yield: 15 g (80.2%)

Identification (by IR, vs. warfarin acid standard): complies

¹H-NMR test: pattern practically identical to an authentic warfarin sodium clathrate sample, but the integral of the protons relative to the respective methyl groups suggested an equimolar content of IPA in clathrate.

IPA content (by GC): 15.1%

Thermal analysis (by DSC): typical endotherm, similar to those observed with an authentic warfarin sodium 2-propanol clathrate sample appeared around 160°C, suggesting the existence of a clathrate.

EXAMPLE 6: Preparation of Warfarin Sodium 2-Propanol Clathrate

A suitable glass vessel provided with a distillation column and fraction separator was charged with pure warfarin acid (1000 g, 3.25 mole), sodium carbonate (CP, 260 g, 2.45 mole) and 2-propanol (technical grade, 5000 ml).

The mixture was heated to reflux for two hours and then cooled to room temperature. Demineralized water (500 ml) was added and the reaction mixture stirred for ½ hour at room temperature, cooled to below 10°C and rapidly filtered by suction.

The clear, uncolored solution was returned to the vessel, hexane (1500 ml) was added and the mixture heated to boiling with stirring.

A ternary azeotropic mixture began to distill and water was gradually removed from the mixture. Hexane was then removed by a binary azeotropic distillation and warfarin sodium 2-propanol clathrate precipitated.

The solution was filtered with suction, the solids washed with cold 2-propanol, and dried for about 8 hours (vacuum oven, 45-50°C, 10 mm Hg) to yield the pure product as a white crystalline solid.

Yield: 1030 g (88%)
pH of 1% solution: 8.25
Water (by KF): less than 0.1%
IPA content (by GC): 8.15%
Clarity of alkaline solution: complies

Color (by UV): < 0.1 AU
Related substances (TLC): not detected

The product complied with the pharmacopeial requirements.

EXAMPLE 7: Preparation of Warfarin Sodium 2-Propanol Clathrate

A suitable glass vessel provided with a distillation column was successively charged with 2-propanol (technical grade, 7.7 L), pure warfarin acid, (1.54 kg, 5 mole), sodium carbonate (0.34 kg, 3.2 mole) and demineralized water (0.22 L).

The mixture was refluxed for two hours with stirring.

The heating was then stopped and the hot mixture rapidly filtered. The clear warm filtrate was returned to the vessel, the solution heated while stirring, and the water slowly removed by a binary azeotropic distillation, with a high reflux ratio. The solvent removed by distillation was replaced by adding fresh 2-propanol and the suspension stirred at reflux for another hour or two.

Heating was stopped and the mixture gradually cooled to below 10°C. The solid was filtered, washed with cold solvent and dried in a vacuum oven (45-50°C, 10 mm Hg) for 6-10 hours, to give pure warfarin sodium 2-propanol clathrate as a white, crystalline powder.

Yield: 1.5 kg (83%)
pH of 1% solution: 8.3
Clarity of alkaline solution: complies
Color (by UV): < 0.1 AU

Water (by KF): not more than 0.1%
IPA content (by GC): 8.2%
Related substances (TLC): not detected

Analysis: Complied with pharmacopeial requirements.

EXAMPLE 8: Preparation of Warfarin Sodium 2-Propanol Clathrate

A suitable glass flask provided with a distillation column was charged with 2-propanol (8 L, technical grade or recovered) containing about 1%-2% water (v/v), sodium carbonate (CP, 175 g, 1.65 mole) and pure warfarin acid (1 kg, 3.25 mole).

The mixture was heated with stirring and refluxed for two hours.
The unclear solution was left to cool to around 30°C and rapidly filtered by suction. The almost uncolored filtrate was returned to the flask, heating restarted, and azeotropic distillation of 2-propanol/water initiated. This distillation was continued until the volume in the flask reached about $\frac{1}{3}$ of the initial volume and a thick suspension obtained.

The suspension was cooled to below 10°C, and worked up as previously described (examples 4-5) to give the desired pure warfarin sodium 2-propanol clathrate, as a white crystalline solid.

**Yield:** 995 g (85%)

**pH** of 1% solution: 7.9-8.0

**Clarity** of the alkaline solution: complies

**Color** (by UV): less than 0.1 AU

**Water** (by KF): 0.1%

**Related substances** (TLC): not detected

**Analysis:** Complied with the pharmacopeial requirements.

The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. All examples presented are representative and non-limiting. The above-described embodiments of the invention may be modified or varied, and elements added or omitted, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.
WHAT IS CLAIMED IS:

1. A process for preparing pure warfarin acid comprising the steps of:
   (a) providing crude warfarin acid suspended in a water immiscible solvent,
   (b) combining the water immiscible solvent with an alkaline aqueous phase,
   (c) extracting the crude warfarin acid into the alkaline aqueous phase as a warfarin salt,
   (d) separating the aqueous phase from the water immiscible solvent,
   (e) diluting the aqueous phase with a lower alkyl alcohol,
   (f) acidifying the diluted aqueous/lower alkyl alcohol phase with an aqueous acid to give a suspension of pure warfarin acid.

2. The process according to claim 1, further comprising filtering the aqueous phase after separating the aqueous phase from the water immiscible solvent.

3. The process according to claim 1, wherein the diluted aqueous phase is acidified at a temperature above room temperature.

4. The process according to claim 1, further comprising cooling the suspension of pure warfarin acid.

5. The process according to claim 1, further comprising filtering pure warfarin acid.

6. The process according to claim 1, wherein the water immiscible solvent is toluene.

7. The process according to claim 1, wherein the alkaline aqueous phase is dilute sodium hydroxide.

8. The process according to claim 1, wherein the aqueous phase is heated to a temperature of from about 20°C to about 60°C before diluting with the lower alkyl alcohol.
9. The process according to claim 1, wherein the aqueous phase is heated to a temperature of from about 40°C to about 50°C before diluting with the lower alkyl alcohol.

10. The process of claim 1, wherein the lower alkyl alcohol is added to a concentration of about 50%.

11. The process according to claim 1, wherein the lower alkyl alcohol is selected from the group consisting of methanol, ethanol and 2-propanol.

12. The process according to claim 1, wherein the lower alkyl alcohol is 2-propanol.

13. The process according to claim 1, wherein the aqueous acid is selected from the group consisting of hydrochloric acid, sulfuric acid and phosphoric acid.

14. The process according to claim 1, wherein the aqueous acid is sulfuric acid.

15. The process according to claim 4, wherein the suspension of pure warfarin acid is cooled below room temperature.

16. The process according to claim 4, wherein the suspension of pure warfarin acid is cooled to a temperature of between about 5°C and about 10°C.

17. The process according to claim 1, wherein the crude warfarin acid is prepared by a process comprising the step of:

   adding an acid catalyst to a solution of cyclocoumarol in a water miscible solvent containing up to about 50% water at a temperature from about room temperature to about the boiling point of the solvent.

18. The process according to claim 17, wherein the acidic catalyst is 4-toluenesulfonic acid.
19. The process according to claim 17, wherein the water miscible solvent is butanone or acetone.

20. A process for the preparation of a pure warfarin salt or clathrate thereof, comprising the steps of: reacting pure warfarin acid prepared according to the process of claim 1 with a metal carbonate in a nonaqueous solvent, and removing unreacted metal carbonate.

21. The process according to claim 20, wherein the nonaqueous solvent contains from about 0.5% to about 10% water.

22. The process according to claim 20, wherein the nonaqueous solvent contains from about 0.5% to about 5% water by volume.

23. The process according to claim 20, wherein the nonaqueous solvent contains from about 1% to about 3% water by volume.

24. The process according to claim 20, wherein the ratio of molar equivalents of metal carbonate to warfarin acid is from about 0.9 to about 2.

25. The process according to claim 20, wherein ratio of molar equivalents of metal carbonate to warfarin acid is from about 1.0 to about 1.3.

26. The process according to claim 20, further comprising the step of precipitating the pure warfarin salt or clathrate thereof.

27. The process according to claim 26, wherein the pure warfarin salt is precipitated by removing the solvents using azeotropic distillation.

28. The process according to claim 20, wherein the pure warfarin salt is precipitated by adding a nonpolar solvent selected from the group consisting of hexane, cyclohexane and heptane.
29. The process according to claim 27, wherein the salt is precipitated by azeotropic distillation of a ternary azeotrope of water, 2-propanol and a hydrocarbon selected from the group consisting of hexane, heptane and cyclohexane.

30. The process according to claim 20, wherein the warfarin salt is warfarin sodium, the metal carbonate is sodium carbonate and the nonaqueous solvent is selected from the group consisting of ethanol, acetonitrile, acetone and butanone.

31. The process according to claim 20, wherein the warfarin salt is warfarin potassium, the metal carbonate is potassium carbonate and the nonaqueous solvent is 2-propanol.

32. The process according to claim 20, wherein the warfarin salt clathrate is warfarin sodium 2-propanol clathrate, the metal carbonate is sodium carbonate and the nonaqueous solvent is 2-propanol.

33. A process for the preparation of pure warfarin lithium 2-propanol clathrate comprising the step of: reacting pure warfarin acid prepared according to claim 1 with lithium 2-propoxide in anhydrous 2-propanol.

34. Pure warfarin acid prepared by the steps of:
(a) providing crude warfarin acid suspended in a water immiscible solvent,
(b) combining the suspension with an alkaline aqueous phase,
(c) extracting warfarin acid into the aqueous phase as a warfarin salt,
(d) separating the aqueous phase,
(e) diluting the aqueous phase with a lower alkyl alcohol,
(f) acidifying the diluted aqueous/lower alkyl alcohol phase using an aqueous acid to give a suspension of pure warfarin acid.

35. The pure warfarin acid of claim 34, wherein the preparation further comprises: filtering the aqueous phase before diluting with the lower alkyl alcohol.
36. The pure warfarin acid of claim 34, wherein the aqueous phase is heated to a temperature at or above room temperature before diluting with the lower alkyl alcohol.

37. The pure warfarin acid of claim 34, wherein the preparation further comprises cooling the suspension of pure warfarin acid.

38. The pure warfarin acid of claim 34, wherein the preparation further comprises filtering pure warfarin acid.

39. The pure warfarin acid of claim 34, in a form having greater purity than required by the U.S. Pharmacopoeia.

40. A process for preparing pure warfarin acid comprising:
   a step for preparing a suspension of crude warfarin acid in a water immiscible solvent,
   a step for isolating warfarin salt thereof in an alkaline aqueous phase,
   a step for separating the aqueous phase,
   a step for achieving a dilution of the aqueous phase with a lower alkyl alcohol,
   a step for producing a suspension of pure warfarin acid by acidifying the diluted aqueous/lower alkyl alcohol phase with an aqueous acid, and,
   a step for obtaining pure warfarin acid from the suspension.

41. The process according to claim 40, wherein the step for obtaining pure warfarin acid from the suspension comprises a step for obtaining a cooled suspension.

42. The process according to claim 40, further comprising a step for filtering the aqueous phase before the step for achieving a dilution of the aqueous phase.

43. Pure warfarin acid prepared by the steps of:
   (a) suspending crude warfarin acid in toluene,
   (b) extracting the crude warfarin acid into dilute aqueous sodium hydroxide as a warfarin salt,
   (c) separating the aqueous solution,
(d) heating the aqueous solution to a temperature of from about 20°C to about 60°C,

(e) diluting the aqueous phase with 2-propanol to a concentration of from about 40% to about 50% 2-propanol while maintaining the temperature at from about 20°C to about 60°C, and

(f) acidifying the 2-propanol/aqueous solution with sulfuric acid to a constant pH at a temperature of from about 20°C to about 60°C to give a suspension of pure warfarin acid.

44. The pure warfarin acid of claim 43, wherein the preparation further comprises the steps of:

(g) cooling the suspension to a temperature of less than about 10°C, and

(h) filtering pure warfarin acid.

45. A method for making a pharmaceutical warfarin preparation comprising preparing pure warfarin acid from crude warfarin acid by a process comprising the steps of

(a) providing crude warfarin acid suspended in a water immiscible solvent,

(b) combining the water immiscible solvent with an alkaline aqueous phase,

(c) extracting the crude warfarin acid into the alkaline aqueous phase as a warfarin salt,

(d) separating the aqueous phase from the water immiscible solvent,

(e) diluting the aqueous phase with a lower alkyl alcohol, and

(f) acidifying the diluted aqueous/lower alkyl alcohol phase with an aqueous acid to give a suspension of pure warfarin acid,

converting the pure warfarin acid to a pharmaceutically acceptable warfarin derivative, and preparing a pharmaceutical warfarin dosage form comprising said warfarin derivative.

46. The method of claim 45, wherein the pharmaceutically acceptable warfarin derivative is selected from the group consisting of warfarin salts and clathrates.

47. The method of claim 46, wherein the warfarin salts and clathrates comprises at least one warfarin salt or clathrate selected from the group consisting of warfarin potassium, warfarin sodium, warfarin sodium 2-propanol clathrate, warfarin lithium, and warfarin lithium 2-propanol clathrate.
48. The method of claim 45, wherein the dosage form is selected from the group consisting of tablets, capsules, geltabs, powders, granules, solutions and suspensions.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

| IPC 7 | C07D311/20 |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched: (classification system followed by classification symbols)

| IPC 7 | C07D |

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 4 113 744 A (BADRAN NASRI W) 12 September 1978 (1978-09-12) cited in the application</td>
<td>34-39, 43, 44</td>
</tr>
<tr>
<td></td>
<td>* see claim 12 * the whole document</td>
<td>1-33, 45-48</td>
</tr>
<tr>
<td>Y</td>
<td>US 2 765 321 A (PAUL LINK KARL ET AL) 2 October 1956 (1956-10-02) cited in the application * see claims 1 and 2 * the whole document</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-33, 45-48</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>US 2 777 859 A (PAUL LINK KARL) 15 January 1957 (1957-01-15) cited in the application * see claim 1 * the whole document</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-33, 45-48</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>Further documents are listed in the continuation of box C.</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>Patent family members are listed in annex.</td>
<td></td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *I* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

**Date of the actual completion of the international search**

25 June 2002

**Date of mailing of the international search report**

05/07/2002

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Stellmach, J
## INTERNATIONAL SEARCH REPORT

### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication where appropriate of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>FR 1 397 213 A (FROSST &amp; CO CHARLES E) 30 April 1965 (1965-04-30) cited in the application <em>see claims 1-5</em> the whole document</td>
<td>1-33, 45-48</td>
</tr>
<tr>
<td>Y</td>
<td>WO 97 24347 A (HOECHST CELANESE CORP) 10 July 1997 (1997-07-10) cited in the application <em>see claim 1-3, step c)</em> the whole document</td>
<td>1-33, 45-48</td>
</tr>
<tr>
<td>Y</td>
<td>ONISHI, M. ET AL.: &quot;Structure-Activity-Relationship between the Hydrophobicity of Alkali Metal Salts of Warfarin '3-(alpha-Acetonyl-benzyl)-4-hydroxycoumarin! and the Effectiveness of the Taste Response of These Salts in Mice&quot; BIOSCI.BIOTECH.BIOCHEM., vol. 59, no. 6, 1995, pages 995-1001, XP001083557 <em>see p.995, left col., last 6 lines</em> the whole document</td>
<td>1-33, 45-48</td>
</tr>
<tr>
<td>A</td>
<td>US 4 826 689 A (VIOLANZO MICHAEL R) 2 May 1989 (1989-05-02) <em>see claim 1</em> the whole document</td>
<td>1-33, 45-48</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>US 4113744 A</td>
<td>12-09-1978</td>
<td>AU 8356175 A 832395 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BE 7504996 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 1077502 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 2535228 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 440221 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2281754 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 1513399 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IN 141166 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 51041361 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 58035967 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LU 73199 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NL 7509661 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 7504795 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 2765321 A</td>
<td>02-10-1956</td>
<td>NONE</td>
</tr>
<tr>
<td>US 2777859 A</td>
<td>15-01-1957</td>
<td>NONE</td>
</tr>
<tr>
<td>FR 1397213 A</td>
<td>30-04-1965</td>
<td>BE 644186 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 1056291 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 4997454 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 579166 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4501285 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 1282405 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0169618 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0544657 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 1973762 C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 7002209 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 62027032 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6501872 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 80494 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9203380 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 55921 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3579385 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 543354 D0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 8607007 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 75250 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 212151 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 80494 B</td>
</tr>
</tbody>
</table>